Published on 25/12/2025
How to Create a Structured SIV Agenda with Key Components for Clinical Trials
A well-structured Site Initiation Visit (SIV) is essential for a smooth trial launch. The SIV agenda is not just a checklist—it’s a strategic tool that aligns all stakeholders, ensures regulatory compliance, and guarantees the site is ready for subject recruitment. This tutorial offers a comprehensive SIV agenda template and explains the key components sponsors, CROs, and site staff must cover to meet USFDA and CDSCO expectations.
Purpose of the SIV Agenda
The agenda serves as a blueprint for the SIV meeting and ensures that all study-critical elements are addressed, including:
- Study protocol overview and compliance discussions
- Informed consent procedures and ethics approvals
- Investigational product (IP) handling and accountability
- Electronic data capture (EDC) system training
- Monitoring plan and CRA communication protocols
- Essential documentation verification
An effective agenda reflects regulatory and operational priorities and can be customized using templates from Pharma SOPs.
Recommended SIV Agenda Template
- Welcome and Introductions
- Overview of the Clinical Study
- Protocol Training and Key Endpoints
- Eligibility Criteria and Enrollment Strategy
- Informed Consent Process
- Safety Reporting and Adverse Events
- Investigational Product Management
- Essential Documents and Regulatory Binder Review
- Electronic Systems Overview: EDC, IWRS, ePRO
- Monitoring Plan and CRA Communication
- Site Responsibilities and Sponsor Expectations
- Q&A and Action Items
- SIV Acknowledgment and Attendance Signatures
Detailed
1. Welcome and Introductions
- Facilitated by the CRA or sponsor representative
- All team members and their roles should be clearly introduced
2. Overview of the Clinical Study
- Purpose and objectives of the clinical trial
- Therapeutic area background
- Study design (e.g., randomized, blinded, multicenter)
3. Protocol Training and Key Endpoints
- Visit schedule, timelines, and procedures
- Primary and secondary endpoints
- Deviations and how to avoid them
4. Eligibility Criteria and Enrollment Strategy
- Inclusion/exclusion criteria breakdown
- Screening checklist and documentation flow
- Patient recruitment plans and tools
5. Informed Consent Process
- ICF version control and signature requirements
- Re-consent triggers (e.g., protocol amendments)
- PI responsibilities and delegated personnel
6. Safety Reporting and Adverse Events
- Definitions: AE, SAE, SUSAR
- Timelines and contact persons for reporting
- Documentation in source and CRFs
7. Investigational Product Management
- IP storage, temperature monitoring, and documentation
- Drug accountability logs and return procedures
- Blinding and emergency unblinding processes
8. Essential Documents and Regulatory Binder Review
- 1572 form, CVs, GCP training certificates, delegation logs
- IRB/EC approval letters and annual renewals
- Signed Investigator Agreement
9. Electronic Systems Overview
- Access to EDC, IWRS/IRT, ePRO, eTMF systems
- Password setup and training status
- Helpdesk contacts for system support
Sites should confirm system access status and login capability prior to SIV with support from Stability Studies for validation documentation.
10. Monitoring Plan and CRA Communication
- Frequency of site monitoring visits (SMVs)
- Remote monitoring and source data verification (SDV)
- CRA contact protocol and escalation pathways
11. Site Responsibilities and Sponsor Expectations
- Enrollment targets and key milestones
- Data entry timelines (e.g., within 48 hours of visit)
- Compliance with protocol, GCP, and audit readiness
12. Q&A and Action Items
- Site staff should clarify doubts and raise concerns
- Review action points and responsible parties
13. SIV Acknowledgment and Attendance Log
- All attendees sign the acknowledgment form
- Document is filed in the ISF and shared with sponsor
Best Practices for SIV Agenda Implementation
- Customize the agenda based on study phase and complexity
- Send agenda and reading materials to the site 5–7 days prior
- Include visual aids, study flowcharts, and role-specific slides
- Encourage active participation during training sections
- Use checklists and trackers to document each agenda item
Common Pitfalls to Avoid
- Overloading the agenda with unnecessary items
- Failing to confirm attendee availability ahead of time
- Skipping IP training or safety reporting discussions
- Unstructured Q&A time leading to missed clarifications
Conclusion
A well-organized SIV agenda ensures that no aspect of trial readiness is overlooked. It provides a foundation for consistent study conduct, sponsor confidence, and audit preparedness. Whether you’re a CRA, site manager, or investigator, following a structured agenda will help streamline your SIVs and support long-term trial success.